146 studies found for:    daniel lee | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma
Conditions: Glioma;   Glioblastoma;   Glioblastoma Multiforme
Intervention: Drug: FDOPA PET
2 Recruiting Multi-center Prospective Study to Evaluate Outcomes of the Moderate to Severely Calcified Coronary Lesions (MACE)
Condition: Coronary Artery Disease
Intervention:
3 Recruiting Auditory Brainstem Implant (ABI) in Adult Non-Neurofibromatosis Type 2 Subjects
Condition: Bilateral Hearing Loss for Causes Other Than Tumors
Intervention: Device: Nucleus 24 Auditory Brainstem Implant (ABI)
4 Recruiting Absorb IV Randomized Controlled Trial
Conditions: Coronary Artery Disease;   Coronary Artery Stenosis;   Coronary Disease;   Coronary Stenosis
Interventions: Device: Absorb BVS;   Device: XIENCE
5 Recruiting 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: 177Lu-J591;   Drug: Ketoconazole;   Drug: Hydrocortisone;   Drug: 111In-J591
6 Recruiting Auditory Brainstem Implant (ABI) in Pediatric Non-Neurofibromatosis Type 2 Subjects
Condition: Bilateral Hearing Loss for Causes Other Than Tumors
Intervention: Device: Nucleus 24 Auditory Brainstem Implant (ABI)
7 Unknown  Vitamin E Supplementation in Burn Patients
Condition: Burn Injury
Intervention: Dietary Supplement: dl-alpha-tocopheryl acetate
8 Recruiting Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma
Conditions: ALL;   B Cell Lymphoma;   Leukemia;   Large Cell Lymphoma;   Non-Hodgkin Lymphoma
Intervention: Biological: Anti-CD19- CAR
9 Recruiting S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma
Condition: Lymphoma
Interventions: Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate;   Other: R-CHOP regimen;   Other: laboratory biomarker analysis;   Radiation: fludeoxyglucose F 18;   Radiation: selective external radiation therapy;   Radiation: yttrium Y 90 ibritumomab tiuxetan
10 Recruiting Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Procedure: therapeutic thoracoscopy;   Procedure: videothoracoscopy
11 Recruiting Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
Condition: Breast Cancer
Interventions: Drug: LEE011;   Drug: Letrozole;   Drug: BYL719
12 Recruiting LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)
Condition: Tumors With CDK4/6 Pathway Activation
Intervention: Drug: LEE011
13 Recruiting Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2)
Condition: Advanced, Metastatic Breast Cancer
Interventions: Drug: LEE011;   Drug: Letrozole;   Drug: LEE011 Placebo
14 Recruiting A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients
Condition: Chronic Myeloid Leukemia
Interventions: Drug: 600mg/day of Imatinib;   Drug: 400mg/day of Imatinib
15 Recruiting S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
Condition: Kidney Cancer
Interventions: Drug: everolimus;   Other: placebo
16 Recruiting ExploR™ Modular Radial Head Data Collection
Condition: Elbow Fracture
Intervention: Device: Explore Modular Radial Head
17 Recruiting Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
Conditions: Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Drug: Bendamustine Hydrochloride;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Biological: Rituximab
18 Recruiting Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Conditions: Atypical Carcinoid Tumor;   Foregut Carcinoid Tumor;   Hindgut Carcinoid Tumor;   Lung Carcinoid Tumor;   Metastatic Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Tumor G1;   Midgut Carcinoid Tumor;   Recurrent Digestive System Neuroendocrine Tumor G1;   Recurrent Merkel Cell Carcinoma;   Regional Digestive System Neuroendocrine Tumor G1;   Stage IIIA Merkel Cell Carcinoma;   Stage IIIB Merkel Cell Carcinoma;   Stage IV Merkel Cell Carcinoma;   Thyroid Gland Medullary Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Pazopanib Hydrochloride;   Other: Placebo;   Other: Quality-of-Life Assessment
19 Recruiting Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer
Conditions: Recurrent Non-small Cell Lung Cancer;   Squamous Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Biological: anti-B7H1 monoclonal antibody MEDI4736;   Drug: PI3 kinase inhibitor GDC-0032;   Drug: palbociclib isethionate;   Drug: FGFR inhibitor AZD4547;   Biological: rilotumumab;   Drug: docetaxel;   Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis
20 Recruiting S0820, Adenoma and Second Primary Prevention Trial
Condition: Colorectal Neoplasms
Interventions: Drug: Eflornithine placebo & sulindac placebo;   Drug: eflornithine & sulindac placebo;   Drug: Eflornithine placebo & sulindac;   Drug: Eflornithine plus sulindac

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years